- Lobbying
- Lobbying by Genentech
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jeff MacKinnon | LD and LA Rep. Joe Barton (R-Texas) LD & LA Rep. Joe Barton (RTexas) |
Jeff Mortier | Prof Staff on E&C Cmte and LA Rep Whitfield |
Joseph Vasapoli | Min.Counsel, Energy&Comm, Special Asst. DOE Min.Counsel, Energy&Comm, Special Asst. DOE Min. Counsel, Energy&Comm, Special Asst. DOE |
Jeffery Mortier | Prof Staff on E&C Cmte and LA Rep Whitfield, Intern for Devin Nunes Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin Nunes |
Jeffrey MacKinnon | LD and LA Rep. Joe Barton (R-Texas) |
Sarah Walter | Former Legislative Director/Chief Counsel, Sen. John Breaux |
J. Daniel Walsh | LD Rep. Wayne Gilchrest and LA Rep. Jack Buechner |
Edward Whitfield | U.S. Representative (21 yrs.) U.S. Representatives (21 yrs.) |
Kristen O'Neill | Health Policy Advisory, LA, Staff Assistant Gene Greene (D-TX) Staff Assistant GK Butterfield (D-NC) |
Kristen Bautz | Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz |
Dylan Moore | Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8) Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10) |
Jody Gale | n/a |
William Krieger | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Concerns regarding Meicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act". Monitor Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies..
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Concerns regarding Meicare payment policies for Part B drugs. Issues related to the 340B Drug discount program. Issues related to
the implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act". Monitor
Drug Safety and pedigree legislation. Monitor legislation and oversight on compounding pharmacies..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate